Biogen to Focus on RRMS Disease Management, Treatment at Upcoming Conference

Biogen plans to present new clinical data at the 67th American Academy of Neurology (AAN) Annual Meeting in Washington D.C., April 18 – 25, 2015, including numerous presentations focusing on multiple sclerosis.  In a company press release, Biogen stated “At AAN, we will feature new scientific data, including research highlighting the efficacy and favorable safety profile of TECFIDERA, the most prescribed oral medicine for relapsing MS in the US.”

According to Kate Dawson, vice president, US Medical Affairs “Biogen is committed to exploring ways to transform the care of patients living with MS and other neurodegenerative diseases both through its broad portfolio of MS therapies and extensive pipeline, as well as innovative company initiatives. At AAN, we will feature new scientific data, including research highlighting the efficacy and favorable safety profile of TECFIDERA, the most prescribed oral medicine for relapsing MS in the US.”

TECFIDERA is an oral medication for relapsing MS. The medication has received approval in the United States, the European Union, Canada, Australia and Switzerland.

Biogen also plans to present other data regarding patient care of people with MS, and presentations will include discussions of the current “state of MS” and will highlight why patient-healthcare provider interactions are so important.

Overall, the company will present the following MS data:

1) Emerging approaches to MS management

2) Tecfidera

• Clinical Efficacy in Newly Diagnosed Relapsing-Remitting Multiple Sclerosis Patients with Highly Active Disease
• Long-Term Efficacy of Delayed-Release Dimethyl Fumarate for Relapsing-Remitting Multiple Sclerosis According to Prior Therapy

3) Tysabri

• Disease Course in Multiple Sclerosis (MS) Patients Switching from Fingolimod to Natalizumab
• Natalizumab-Treated Patients with Multiple Sclerosis Have Low Rates of Brain Volume Decrease and Low MRI Disease Activity

4) Plegridy

• Long-Term Safety and Tolerability of Peginterferon Beta-1a
• Long-Term Efficacy in MRI and No Evidence of Disease Activity Outcomes in Patients with Relapsing-Remitting Multiple Sclerosis Treated with Peginterferon Beta-1a

5) Zinbryta

• Daclizumab HYP Versus Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis
• Safety and Tolerability Results

6) Anti-LINGO-1

• Evidence of Remyelination with the Anti-LINGO-1 Monoclonal Antibody BIIB033 after Acute Optic Neuritis 
• Efficacy Analysis of the Anti-LINGO-1 Monoclonal Antibody BIIB033 in Acute Optic Neuritis

[adrotate group=”4″]

Anti-LINGO-1 is a medication that restores myelin — a fatty substance that facilitates nerve cell impulses by wrapping around them and providing insulation. Recent trial results indicate that anti-LINGO-1 could help to repair the damaged visual system.

RENEW is one component of Biogen Idec’s program to develop anti-LINGO-1, which includes the SYNERGY multiple sclerosis trial. SYNERGY is an ongoing, separate Phase 2 study of anti-LINGO-1 in people with relapsing multiple sclerosis. Biogen Idec expects results for the SYNERGY trial in 2016.

The presentations underscore Biogen’s continuing commitment to treating MS, using multiple therapies and approaches. At this particular conference, Biogen will be focusing predominantly on the Relapsing-Remitting form of the disease, which the majority of MS are diagnosed with.